Rare cervical teratoma tumor develops in the neck of fetuses or newborns, causing breathing problems. A lifesaving procedure is often required during delivery.

But the episode was a reminder that the king is 76 and continues to undergo treatment for an undisclosed form of cancer diagnosed more than a year ago. Advertisement Advertisement That reality has ...

Huston didn’t disclose the type of cancer, but recalled the overwhelming gravity of first receiving her diagnosis. “That was a very serious moment for me,” she told the outlet. “I managed to survive ...

INDIANAPOLIS, Ind. (Ivanhoe Newswire) - A cervical teratoma is a rare, large tumor that develops on a baby’s neck while in the womb. It often grows as the baby grows, causing the airway to be ...

CT-95 is a bispecific antibody targeting mesothelin-expressing cancers, engaging T cells to attack tumors. The phase 1 trial in San Antonio will evaluate CT-95's safety, tolerability, pharmacokinetics ...

The state Department of Public Health is “in communication” with Newton-Wellesley Hospital after a reported group of nurses were diagnosed with brain tumors. The diagnosed nurses have worked ...

Ivanhoe Little Fighter: Cancer Scare in the Womb Posted: April 8, 2025 | Last updated: April 8, 2025 A cervical teratoma is a rare, large tumor that develops on a baby’s neck while in the womb ...

11 nurses from Newton-Wellesley Hospital reported brain tumors or related health issues after working in the same labor and delivery unit. The hospital says an extensive internal and external ...

Run to Share 2025 intends to raise funds for blood transfusion needed by children with cancer. The fund-raising is in coordination with the UP-Philippine General Hospital’s Department of ...

BOSTON (WKRC) — A hospital is investigating after five nurses from the same floor developed brain tumors. Mass General Brigham Newton-Wellesley Hospital, located about 10 miles west of Boston ...

The FDA cleared the investigational new drug application for ALX2004, with phase 1 trials expected to begin in mid-2025 for EGFR+ solid tumors. The FDA has cleared the investigational new drug (IND) ...